Rongchang Pharmaceutical Engineering

RemeGen is a leading clinical-stage biopharmaceutical company headquartered in Yantai, China, specializing in the discovery and development of innovative biologics for autoimmune diseases, oncology, and ophthalmology. The company is a global pioneer in antibody-drug conjugates (ADCs) and fusion proteins, with two landmark products already commercialized: Telitacicept (RC18), a first-in-class BAFF/APRIL dual inhibitor, and Disitamab vedotin (RC48), a HER2-targeted ADC. RemeGen's robust pipeline is built upon three proprietary technology platforms—ADC, antibody, and fusion protein—enabling the development of highly differentiated therapies. With a significant global partnership with Pfizer (via Seagen) and a strong presence in both Chinese and international markets, RemeGen is positioned as a key player in the next generation of precision medicine.